ALDX
(NASDAQ)
7.95
-0.1500   (-1.85%)
After Hours: 8.10 0.1500 (1.89%)
Volume (24h) Market Cap. Day Range 52w Range
970.38K 307.13M 7.84 - 8.70 1.48 - 8.70
Oct-16-20 08:20PM Why Aldeyra Therapeutics Stock Soared TodayMotley Fool
Oct-13-20 06:38PM Hedge Funds Have Never Been This Bullish On Aldeyra Therapeutics Inc (ALDX)Insider Monkey
Oct-02-20 03:30PM Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year?Zacks
Sep-30-20 11:55AM 4 Small Drug Stocks to Look Out For Amid Coronavirus UncertaintyZacks
Sep-29-20 02:30PM Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100%TipRanks
Sep-16-20 03:30PM Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?Zacks
12:00PM Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech SummitBusiness Wire
Sep-10-20 12:00PM Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor ConferencesBusiness Wire
Sep-09-20 12:00PM Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 PatientsBusiness Wire
Sep-03-20 12:00PM Aldeyra to Participate in Citi’s 15th Annual BioPharma Virtual ConferenceBusiness Wire
Aug-25-20 03:30PM Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year?Zacks
Aug-12-20 04:00PM Aldeyra Therapeutics, Inc. (ALDX) Upgraded to Buy: Here's What You Should KnowZacks
Aug-06-20 02:09PM Aldeyra's (ALDX) Q2 Earnings Beat Estimates, Pipeline in FocusZacks
11:00AM Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire
Aug-04-20 02:07PM Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?Zacks
12:00PM Aldeyra Therapeutics to Participate in Upcoming Virtual Investor ConferencesBusiness Wire
Jul-30-20 12:00PM Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate UpdateBusiness Wire
Jul-14-20 12:00PM Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity PartnersBusiness Wire
08:32AM Aldeyra Spikes 10% In Pre-Market On New Perceptive StakeSmarterAnalyst
Jul-13-20 08:05PM Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020Business Wire
Jul-08-20 01:28AM Aldeyra Therapeutics Inc (ALDX): Hedge Funds In Wait-and-See ModeInsider Monkey
Jul-07-20 12:00PM Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye DiseaseBusiness Wire
Jul-03-20 03:15PM What Kind Of Investors Own Most Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)?Simply Wall St.
Jul-01-20 01:36PM Zynerba's Zygel Fails in Phase III Fragile X Syndrome StudyZacks
Jun-22-20 04:00PM What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Strong Buy StockZacks
Jun-18-20 02:12PM Aclaris Gets FDA Nod to Start Investigator-led Coronavirus StudyZacks
Jun-15-20 12:00PM Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease ProgramBusiness Wire
Jun-11-20 12:37AM FibroGen (FGEN) in Focus: Stock Moves 6.5% HigherZacks
Jun-07-20 10:28PM Edited Transcript of ALDX earnings conference call or presentation 7-May-20 12:00pm GMTThomson Reuters StreetEvents
Jun-04-20 12:00PM Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye DiseaseBusiness Wire
Jun-03-20 01:04PM Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in SessionZacks
12:00PM Aldeyra Therapeutics to Present at the Jefferies Virtual Healthcare ConferenceBusiness Wire
May-27-20 01:49PM 3 “Strong Buy” Biotech Stocks Under $5 With Explosive Upside PotentialTipRanks
06:37AM Edited Transcript of ALDX earnings conference call or presentation 7-May-20 12:00pm GMTThomson Reuters StreetEvents
May-27-20 03:09AM Edited Transcript of ALDX earnings conference call or presentation 7-May-20 12:00pm GMTThomson Reuters StreetEvents
May-20-20 09:24PM Covid Report: This Biotech Says Its Coronavirus Drug Topped RemdesivirInvestor's Business Daily
05:16PM Covid Report: The Next Remdesivir? This Tiny Biotech Is Working On ItInvestor's Business Daily
May-20-20 03:00PM Covid Report: The Next Remdesivir? Aldeyra Therapeutics Is Working On ItInvestor's Business Daily
12:12PM The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic TestBenzinga
May-20-20 11:00AM Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch MeetingBusiness Wire
05:48AM Aldeyra Explodes 30% After-Hours Ahead Of Covid-19 Update TodaySmarterAnalyst
May-19-20 08:05PM Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development UpdateBusiness Wire
May-15-20 12:53PM How Aldeyra (ALDX) Stock Stands Out in a Strong IndustryZacks
May-14-20 02:14PM Top Ranked Momentum Stocks to Buy for May 14thZacks
May-13-20 04:00PM Aldeyra Therapeutics Inc (ALDX) Upgraded to Strong Buy: Here's What You Should KnowZacks
12:17PM Aldeyra's Shares March Higher, Can It Continue?Zacks
May-07-20 11:00AM Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical ProgramsBusiness Wire
Apr-30-20 12:00PM Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate UpdateBusiness Wire
Apr-16-20 10:35AM These Mass. companies are developing COVID-19 treatments and testsAmerican City Business Journals
Apr-15-20 01:47PM Company News for Apr 15, 2020Zacks
Aldeyra Therapeutics, Inc. engages in developing medicines for inflammatory diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase 2b clinical trial for the treatment of dry eye disease, as well as Phase 3 clinical trial for the treatment of noninfectious anterior uveitis. Its reproxalap is also in Phase 2b clinical trial for the treatment of allergic conjunctivitis, as well as Phase 2 clinical trial for the treatment of Sjögren-Larsson Syndrome. Its portfolio consists of ADX-1612, which inhibits heat shock protein 90 for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 and ADX-103. Aldeyra Therapeutics, Inc. has a partnership agreement with Janssen to develop other RASP scavengers for immune-mediated diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Cap:    |  Volume (24h):